Cargando…
Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
Long-acting (lasting extend) diquafosol ophthalmic solution 3% (DQSLX) is administered three times daily versus six times daily for the currently approved diquafosol ophthalmic solution (DQS). We investigated the efficacy and adherence of switching from DQS to DQSLX in patients with dry eye disease....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342394/ https://www.ncbi.nlm.nih.gov/pubmed/37445527 http://dx.doi.org/10.3390/jcm12134495 |
_version_ | 1785072488620752896 |
---|---|
author | Ishikawa, Sho Sasaki, Takanori Maruyama, Takahumi Murayama, Koichiro Shinoda, Kei |
author_facet | Ishikawa, Sho Sasaki, Takanori Maruyama, Takahumi Murayama, Koichiro Shinoda, Kei |
author_sort | Ishikawa, Sho |
collection | PubMed |
description | Long-acting (lasting extend) diquafosol ophthalmic solution 3% (DQSLX) is administered three times daily versus six times daily for the currently approved diquafosol ophthalmic solution (DQS). We investigated the efficacy and adherence of switching from DQS to DQSLX in patients with dry eye disease. We retrospectively enrolled 54 patients (17 men and 37 women) with eye drop prescription changes from DQS to DQSLX between December 2022 and March 2023. The number of eye drops, subjective symptoms, tear breakup time (TBUT), and fluorescein staining scores from baseline to 4 weeks after starting DQSLX were evaluated. Participants then chose between DQSLX and DQS. Patients administered DQSLX three times per day, as listed on the package insert, 88.9% of the time; significantly higher than the 5.6% of patients who used DQS six times per day, as instructed. The DQSLX group showed significant improvements in symptoms and fluorescein staining scores (23.3 ± 20.1 and 0.8 ± 1.7, respectively) compared with the baseline (37.8 ± 24.1 and 1.1 ± 1.5, p = 0.01 and <0.001, respectively). The TBUT in the DQSLX group (5.0 ± 2.5 s) did not significantly improve compared to the DQS group (4.5 ± 1.7 s) (p = 0.75). Fifty-one (94.4%) patients opted to continue DQSLX because of the pleasant feeling of the eye drops, long-lasting moisture, and less frequent administration. The efficacy and adherence of DQSLX was comparable to DQS. |
format | Online Article Text |
id | pubmed-10342394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103423942023-07-14 Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution Ishikawa, Sho Sasaki, Takanori Maruyama, Takahumi Murayama, Koichiro Shinoda, Kei J Clin Med Article Long-acting (lasting extend) diquafosol ophthalmic solution 3% (DQSLX) is administered three times daily versus six times daily for the currently approved diquafosol ophthalmic solution (DQS). We investigated the efficacy and adherence of switching from DQS to DQSLX in patients with dry eye disease. We retrospectively enrolled 54 patients (17 men and 37 women) with eye drop prescription changes from DQS to DQSLX between December 2022 and March 2023. The number of eye drops, subjective symptoms, tear breakup time (TBUT), and fluorescein staining scores from baseline to 4 weeks after starting DQSLX were evaluated. Participants then chose between DQSLX and DQS. Patients administered DQSLX three times per day, as listed on the package insert, 88.9% of the time; significantly higher than the 5.6% of patients who used DQS six times per day, as instructed. The DQSLX group showed significant improvements in symptoms and fluorescein staining scores (23.3 ± 20.1 and 0.8 ± 1.7, respectively) compared with the baseline (37.8 ± 24.1 and 1.1 ± 1.5, p = 0.01 and <0.001, respectively). The TBUT in the DQSLX group (5.0 ± 2.5 s) did not significantly improve compared to the DQS group (4.5 ± 1.7 s) (p = 0.75). Fifty-one (94.4%) patients opted to continue DQSLX because of the pleasant feeling of the eye drops, long-lasting moisture, and less frequent administration. The efficacy and adherence of DQSLX was comparable to DQS. MDPI 2023-07-05 /pmc/articles/PMC10342394/ /pubmed/37445527 http://dx.doi.org/10.3390/jcm12134495 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ishikawa, Sho Sasaki, Takanori Maruyama, Takahumi Murayama, Koichiro Shinoda, Kei Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution |
title | Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution |
title_full | Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution |
title_fullStr | Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution |
title_full_unstemmed | Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution |
title_short | Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution |
title_sort | effectiveness and adherence of dry eye patients who switched from short- to long-acting diquafosol ophthalmic solution |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342394/ https://www.ncbi.nlm.nih.gov/pubmed/37445527 http://dx.doi.org/10.3390/jcm12134495 |
work_keys_str_mv | AT ishikawasho effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution AT sasakitakanori effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution AT maruyamatakahumi effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution AT murayamakoichiro effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution AT shinodakei effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution |